CombIning advaNces in imagiNg With biOmarkers for improVed Diagnosis of Aggressive prosTate cancEr

Conditions

Prostate Cancer

Keywords

MRI, Magnetic resonance imaging, Biomarkers, Fluidics, Diffusion MRI

Brief summary

To enable the paradigm of mp-MRI before biopsy in all patients with suspected prostate cancer by better selecting patients who will benefit from diagnostic MRI and by improving the performance of the mp-MRI itself

Detailed description

Patients will undergo an advanced diffusion-weighted MRI sequence called VERDICT with the intention of better characterising prostate cancer. A panel of serum and urine biomarkers will also be analysed, which we hope will predict those patients who go on have a positive MRI. OBJECTIVES: * To establish a fluidic marker - prostate MRI paradigm which: (i) utilises fluidic markers to rationalise selection of patients with significant prostate cancer; and (ii) improves the diagnostic accuracy of imaging over and above standard multiparametric (mp) MRI * Enable a pathway for rapid clinical evaluation of emerging fluidic markers and exosomes * Assess the repeatability of VERDICT MRI * Ascertain whether VERDICT derived quantitative parameters correlate with quantitative histological parameters * Develop a database of fluidic marker and VERDICT characterised, mp-MRI, histologically validated patients for subsequent exploratory and longitudinal outcome analysis

Saurabh Singh, Harriet Rogers, Baris Kanber, Joey Clemente, Hayley Pye et al. (21 authors)

Radiology2022-08-0230 citations

10.1148/radiol.212536

Evaluation of Proclarix, a prostate cancer risk score, used together with magnetic resonance imaging for the diagnosis of clinically significant prostate cancer.

Hayley Pye, Hashim U. Ahmed, Susan Heavey, Urszula Stopka‐Farooqui, Edward W. Johnston et al. (10 authors)

Journal of Clinical Oncology2020-02-195 citations

10.1200/jco.2020.38.6_suppl.278

INNOVATE: A prospective cohort study combining serum and urinary biomarkers with novel diffusion-weighted magnetic resonance imaging for the prediction and characterization of prostate cancer

Edward W. Johnston, Hayley Pye, Elisenda Bonet-Carné, Eleftheria Panagiotaki, Dominic Patel et al. (24 authors)

BMC Cancer2016-10-2047 citations

10.1186/s12885-016-2856-2

Interventions

OTHERMRI

VERDICT diffusion-weighted microstructure imaging sequence

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

MALE

Age

18 Years to No maximum

Healthy volunteers

No

Inclusion criteria

* Men referred to University College London Hospital (UCLH) for prostate mp-MRI following biopsy elsewhere and biopsy naive men presenting to UCLH with a clinical suspicion of prostate cancer.

Exclusion criteria

* Men unable to have a MRI scan, or in whom artefact would reduce quality of MRI * Men unable to given informed consent * Previous treatment (prostatectomy, radiotherapy, brachytherapy) of prostate cancer * On-going hormonal treatment for prostate cancer * Previous biopsy within 6 months of scheduled mp-MRI

Design outcomes

Primary

Measure	Time frame	Description
Diagnostic accuracy of VERDICT MRI	3 - 6 months (after targeted biopsy or follow up MRI)	Radiological assessment with added VERDICT MRI improves the specificity of mp-MRI for detection of significant prostate cancer by \>10% above standard multi-parametric MRI alone.

Countries

United Kingdom

Outcome results

None listed